Assessment of time-to-treatment-failure (TTF) as a surrogate endpoint for overall survival (OS) to immune checkpoint inhibitor (ICI) regimens in metastatic renal cell carcinoma (mRCC): Findings from an IMDC analysis.

Zachary A. Yochum, Toni K. Choueiri, Connor Wells et al.|Journal of Clinical Oncology|2025

Cited by 0